Overview

Pembrolizumab in Combination With Lenvatinib in Patients With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

Status:
Not yet recruiting

Trial end date:
2029-01-01

Target enrollment:

Participant gender:

Summary

Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.

Phase:

Phase 2

Details

Lead Sponsor:

AGO Research GmbH

Treatments:

Lenvatinib
Pembrolizumab